Human T-lymphotropic virus type I infection

Lancet

Volumn 353, Issue 9168, 1999, Pages 1951-1958

  Manns, Angela ^a,c   Hisada, Michie ^a   La Grenade, Lois ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

^c MSC 7248 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD TRANSFUSION; CENTRAL AMERICA; DERMATITIS; DISEASE ASSOCIATION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; JAPAN; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; RETROVIRUS; REVIEW; SEXUAL BEHAVIOR; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T CELL LEUKEMIA; T CELL LYMPHOMA; UVEITIS; VERTICAL TRANSMISSION; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 0033526648     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)09460-4     Document Type: Review

References (82)

1. Poiesz BJ, Ruscetti FW, Gazder AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-19.
2. Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukemia. Nature 1981; 294: 268-71.
3. Takatsuki K, Uchiyama T, Sagawa K, et al. Adult T-cell leukemia in Japan. In: Seno S, Takaku F, Irino S, eds. Topics in hematology. Amsterdam: Excerpta Medica, 1977: 73-77.
4. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 481-92.
5. Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: antigen in an adult T-cell leukemia cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78: 6476-78.
6. Gallo RC, Kalyanaraman VS, Sarngadharan MG, et al. Association of the human type C retrovirus with a subset of adult T-cell cancers. Cancer Res 1983; 43: 3892-99.
7. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; ii: 407-10.
8. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; i: 1031-32.
9. Mochizuki M, Watanabe T, Yamaguchi K, et al. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res 1992; 83: 236-39.
10. La Grenade L, Hanchard B, Fletcher V, et al. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 1990; 336: 1345-47.
11. Ijichi S, Osame M. Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP): recent perspectives. Int Med 1995; 34: 713-21.
12. Terada K, Katamine S, Eguchi K, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren's syndrome. Lancet 1994; 344:1116-19.
13. Bartholomew C, Cleghorn F, Jack N, Edwards J, Blattner W. Human T-cell lymphotropic virus type I-associated facial nerve palsy in Trinidad and Tobago. Ann Neurol 1997; 41: 806-09.
14. Cann AJ, Chen ISY. Human T-cell leukemia virus types I and II. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology, 3rd edn. Philadelphia: Lippincott-Raven, 1996.
15. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood 1995; 86:3619-39.
16. Manns A, Murphy EL, Wilks R, et al. Detection of early human T-cell lymphotropic virus type I antibody patterns during seroconversion among transfusion recipients. Blood 1991; 77: 896-905.
17. Licensure of screening tests for antibody to human T-lymphotropic virus type I. MMWR Morb Mortal Wkly Rep 1988; 37: 736-47.
18. Lehky TJ, Flerlage N, Katz D, et al. Human T-cell lymphotropic virus type II-associated myelopathy: clinical and immunologic profiles. Ann Neurol 1996; 40: 714-23.
19. Poiesz BJ, Ehrlich GD, Byrns BC, et al. The use of the polymerase chain reaction in the detection, quantification and characterization of human retroviruses. Med Virol 1990; 9: 47-75.
20. Madeleine MM, Wiktor SZ, Goedert JJ, et al. HTLV-I and HTLV-II world-wide distribution: reanalysis of 4,832 immunoblot results. Int J Cancer 1993; 54: 255-60.
21. Blattner WA, Saxinger C, Riedel D, et al. A study of HTLV-I and its associated risk factors in Trinidad and Tobago. J Acquir Immune Defic 1990; 3: 1102-08.
22. Murphy EL, Figueroa JP, Gibbs WN, et al. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I: Demographic determinants. Am J Epidemiol 1991; 133: 1114-24.
23. Mueller N, Okayama A, Stuver S, et al. Findings from the Miyazaki cohort study. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13 (suppl 1): S2-S7.
24. Ho GF, Nomura AMY, Nelson K, et al. Declining seroprevalence and transmission of HTLV-I in Japanese families who immigrated to Hawaii. Am J Epidemiol 1991; 134: 981-87.
25. Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T-cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984; 46: 245-53.
26. Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992; 51: 886-91.
27. Gout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl JMed 1990; 322: 383-88.
28. Kanno M, Nakamura S, Matsuda T. Adult T-cell leukaemia with HTLV-I-associated myelopathy after complete remission of acute myelogenous leukaemia. Lancet 1998; 338: 333.
29. Kamihira S, Nakasima S, Oyakawa Y, et al. Transmission of human T cell lymphotropic virus type I by blood transfusion before and after mass screening of sera from seropositive donors. Vox Sang 1987; 52: 43-44.
30. Hino S, Katamine S, Miyata H, et al. Primary prevention of HTLV-I in Japan. Leukemia 1997 (suppl 3): 57-59.
31. Hino S, Yamaguchi K, Katamine S, et al. Mother-to-child transmission of human T cell leukemia virus type-I. Jpn J Cancer Res (Gann) 1985; 76: 474-80.
32. Wiktor SZ, Pate EJ, Rosenberg PS, et al. Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding. J Hum Virol 1997; 1: 37-44.
33. Murata N, Hakoda E, Machida H, et al. Prevention of human T cell lymphotropic virus type I infection in Japanese macaques by passive immunization. Leukemia 1996; 10: 1971-74.
34. Sawada T, Iwahara Y, Ishii K, et al. Immunoglobulin prophylaxis against milkborne transmission of human T cell leukemia virus type I in rabbits. J infect Dis 1991; 164: 1193-96.
35. Stuver SO, Tachibana N, Okayama A, et al. Heterosexual transmission of human T cell leukemia/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki cohort study. J Infect Dis 1993; 167: 57-65.
36. Stuver SO, Mueller NE. Re: Sexual transmission of human T-lymphotropic virus type I among female prostitutes and among patients with sexually transmitted diseases in Fukuoka, Kyushu, Japan. Am J Epidemiol 1995; 142: 1247-48.
37. Murphy EL, Figueroa JP, Gibbs WN, et al. Sexual transmission of human T-lymphotropic virus type-I (HTLV-I). Ann Intern Med 1989; 111:554-60.
38. Yamaguchi K, Seiki M, Yoshida M, et al. The detection of human T-cell leukemia virus proviral DNA and its application for classification and diagnosis of T-cell malignancy. Blood 1984; 63: 1235-40.
39. Korber B, Okayama A, Donnelly R, et al. Polymerase chain reaction analysis of defective human T-cell leukemia virus type I proviral genomes in leukemic cells of patients with adult T-cell leukemia. J Virol 1991; 65: 5471-76.
40. Wilks R, Hanchard B, Morgan O, et al. Patterns of HTLV-I infection among family members of patients with adult T-cell leukemia/lymphoma and HTLV-I associated myelopathy/tropical spastic paraparesis. Int J Cancer 1996; 65: 272-73.
41. Cleghorn FR, Manns A, Falk R, et al. Effect of human T-lymphotropic virus type I infection on non-Hodgkin's lymphoma incidence. J Natl Cancer Inst 1995; 87: 1009-14.
42. Kondo T, Kono H, Miyamoto N, et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers. Int J Cancer 1989; 43: 1061-64.
43. Pombo de Oliveira MS, Matutes E, Schulz T, et al. T-cell malignancies in Brazil. Clinico-pathological and molecular studies of HTLV-I-positive and -negative cases. Int J Cancer 1995; 60: 823-27.
44. Shimoyama M, and members of the Lymphoma Study Group (1984-1987). Diagnostic criteria and classification of clinical subtypes of adult T-cell leukekmia-lymphoma. Br J Haematol 1991; 79: 428-37.
45. Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13 (suppl 1): S20-S25.
46. White JD, Zaknoen S, Kasten-Sportes C, et al. Infectious complication and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma. Cancer 1995; 75: 1598-607.
47. Gill PS, Harrington W, Kaplan M, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl JMed 1995; 332: 1744-48.
48. Hermine O, Bouscary D, Gessain A, et al. Brief report: Treatment for adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995; 332: 1749-51.
49. Wharfe G, Hanchard B. Zidovudine and interferon therapy for adult T-cell leukaemia/lymphoma: results of a preliminary study at UHWI-Mona. W I Med J 1996; 45: 107-09.
50. Cruickshank EK. A neuropathic syndrome of uncertain origin. W I Med J 1956; 5: 147-58.
51. Report from the Scientific Group on HTLV-I Infection and its Associated Diseases, convened by the Regional Office for the Western Pacific of the World Health Organization in Kagoshima, Japan, 10-15 December 1988. WHO Wkly Epidemiol Rec 1989; 49: 382-83.
52. Nakagawa M, Izumo S, Ijichi S, et al. HTLV-I -associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1995; 1: 50-61.
53. Maloney EM, Cleghorn FR, Morgan OS, et al. Incidence of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr Human Retrovirol 1998; 17: 167-70.
54. Bartholomew C, Cleghorn F, Charles W, et al. HTLV-I and tropical spastic paraparesis. Lancet 1986; 2: 99-100.
55. Sonoda S, Fujiyoshi T, Yashiki S. Immunogenetics of HTLV-I/II and associated diseases. J Acquir Immune Defic Syndr HUm Retrovirol 1996; 13 (suppl 1): S119-S123.
56. Jacobson S. Role of cellular immune responses in the pathogenesis of HTLV-I-associated neurologic disease. In: Hollsberg P, Hafler DA, eds. Human t-cell lymphotropic virus type I. Chichester: John Wiley, 1996: 141-62.
57. Jacobson S, Shida H, McFarlin D, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990; 348: 245-48.
58. Gout O, Gessain A, Iba-Zizen M, Kouzan S, et al. The effect of zidovudine on chronic myelopathy associated with HTLV-I. J Neurol 1991; 238: 108-09.
59. Harrington WJ, Sheramata WA, Snodgrass SR, et al. Tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM): treatment with an anabolic steroid Danazol. AIDS Res Hum Retroviruses 1991; 7: 1031-34.
60. Kataoka A, Imai H, Inayoshi S, Tsuda T. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. J Neurol Neurosurg Psychiatry 1993; 56: 1213.
61. Sweet RD. A pattern of eczema in Jamaica. Br J Dermatol 1966; 78: 93-100.
62. La Grenade L, Manns A, Fletcher V, et al. Clinical, pathologic, and immunologic features of human T-lymphotropic virus type I-associated infective dermatitis in children. Arch Dermatol 1998; 134: 439-44.
63. Hanchard B, LaGrenade L, Carberry C, et al. Childhood infective dermatitis evolving into adult T-cell leukaemia after 17 years. Lancet 1991; 338: 1593-94.
64. La Grenade L, Sonoda S, Miller W, et al. HLA DRB1(Black star)DQB1(Black star) haplotype in HTLV-I associated familial infective dermatitis may predict development of HAM/TSP. Am J Med Genet 1995; 61: 37-41.
65. Mochizuki M, Watanabe T, Yamaguchi K, et al. Uveitis associated with human T-cell lymphotropic virus type I. Am J Ophthamol 1992; 114: 123-29.
66. Kihara K, Tsuruda M, Ono A, et al. Human T-lymphotropic virus type 1 uveitis in children. J Jpn Ophthalmol Soc 1997; 101: 538-43.
67. Ono A, Ikeda E, Mochizuki M, et al. Provirus load in patients with human T-cell leukemia virus type 1 uveitis correlates with precedent Grave's disease and disease activities. Jpn J Cancer Res 1998; 89: 608-14.
68. Sagawa K, Mochizuki M, Masuoka K, et al. Immunopathological mechanisms of human T cell lymphotropic virus type I (HTLV-I) uveitis. J Clin Invest 1995; 95: 852-58.
69. Arisawa K, Soda M, Akahoshi M, et al. Human T-lymphotropic virus type-1 infection, antibody titers and cause-specific mortality among atomic-bomb survivors. Jpn J Cancer Res 1998; 89: 797-805.
70. Kinoshita K, Amagasaki T, Ikeda S, et al. Preleukemic state of adult T-cell leukemia: abnormal T lymphocytosis induced by human adult T cell leukemia-lymphoma virus. Blood 1985; 66: 120-27.
71. Takemoto S, Matsuoka M, Yamagushi K, Takatsuki K. A novel diagnostic method of adult T cell leukemia: monoclonal integration of human T-cell leukemia virus type I provirus DNA detection by inverse polymerase chain reaction. Blood 1994; 84: 3080-85.
72. Kaplan JE, Khabbaz RF, Murphy EL, et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 193-201.
73. Hisada M, Okayama A, Shioiri S, et al. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood 1998; 92: 3557-61.
74. Farukawa Y, Osame M, Kubota R, et al. Human T-cell leukemia virus type-1 (HTLV-1) Tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic paraparesis patients as in asymptomatic carriers but a lower level in adult T-cell leukemia cells. Blood 1995; 85: 1865-70.
75. Kubota R, Kawanishi T, Matsubara H, et al. Demonstration of human T lymphotropic virus type (HTLV-I) Tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy-tropical spastic paraparesis patients by intracellular cytokine detection. J Immunol 1998; 161: 482-88.
76. White JD, Johnson JA, Nam JM, et al. Distribution of human leukocyte antigens in a population of black patients with human T-cell lymphotrophic virus type I-associated adult T-cell leukemia/lymphoma. Cancer Epidemiol Biomarkers Prev 1996; 5: 873-77.
77. Manns A, Hanchard B, Morgan OSC, et al. Human leukocyte antigen class II alleles associated with human T-cell lymphotropic virus type I infection and adult T-cell leukemia/lymphoma in a black population. J Natl Cancer Inst 1998; 90: 617-22.
78. Centers for Disease Control and Prevention and the USPHS. Guidelines for counselling persons infected with human T-lymphotrophic virus type I (HTLV-I) and type II (HTLV-II). Working group. Ann Intern Med 1993; 118: 448-54.
79. de Thé G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1993; 9: 381-86.
80. de Thé G, Kazanji M. An HTLV-I/II vaccine: from animal models to clinical trials? J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: S191-S198.
81. Lairmore MD, Lal RB, Kaumaya PTP. Evaluation of immunodiminant epitopes of human T-lymphotropic virus type 1 (HTLV-1) using synthetic peptides. Biomed Pept Prot Nucleic Acids 1995; 1: 117-22.
82. Kazanji M, Moreau J-P, Mahieux R, et al. HTLV-I infection in squirrel monkeys (Saimiri sciureus) using autologous, homologous, or heterologous HTLV-I- transformed cell lines. Virology 1997; 231: 258-66.